Right to Try vs. False Hope

Alison Bateman-House, MPH, PhD

Curious about the alarming and controversial drug access legislation known as “Right to Try”? This webinar breaks down the history and current context for access to experimental treatments and helps make sense of what the passage of Right to Try could mean for patient safety, the Food and Drug Administration (FDA)’s authority to regulate drugs in development, and how it all affects you. We also provide opportunities for how and where you can add your voice to make a difference in opposing this dangerous legislation.

Right to Try is a misleadingly named solution for a problem we don’t have. It does nothing more than allow patients to bypass the FDA to access potentially dangerous or useless treatments outside of the framework and medical oversight of existing programs. Right to Try is really “False Hope”—promising more than what it will give and potentially making it more difficult for proven new drugs to actually get to market for all.

Erica Lessem, MPH

Our featured speakers include Alison Bateman-House, MPH, PhD, a medical ethicist with New York University’s School of Medicine, and Erica Lessem, MPH, Deputy Executive Director with the Treatment Action Group, a New York-based patient advocacy nonprofit. Both women bring extensive public health knowledge and expertise on access to experimental drugs and treatments.